Prevention of complications to Improve outcome in elderly patients with acute stroke - A randomised clinical trial

Submission date Recruitment status [X] Prospectively registered 29/08/2015 No longer recruiting [X] Protocol [X] Statistical analysis plan Registration date Overall study status 22/09/2015 Completed [X] Results [] Individual participant data **Last Edited** Condition category 11/12/2023 Circulatory System

Plain English summary of protocol

Background and study aims

About 85% of strokes are ischemic strokes. Ischemic strokes happen when the arteries that supply the brain with oxygen (the carotid arteries) become narrowed or blocked, causing severely reduced blood flow (ischemia). As we age, a gradual build-up of a sticky substance called plague can occur in one or both of the carotid arteries. When there is a lot of plague, particularly with a rough or irregular surface, blood clots can develop, depriving the brain of oxygen and leading to an acute ischemic stroke (AIS). Intracerebral haemorrhages (ICH) are much less common than ischemic strokes, and make up about 12% of all strokes. ICH happens when a diseased blood vessel in the brain bursts, causing bleeding within the brain. This causes a sudden increase of pressure on the brain, and can quickly lead to unconsciousness and even death. About 70% of patients who suffer from a ICH experience long-term side-effects, and depending on the area of the brain that is affected, it can affect their ability to move, speak or even their cognitive function (memory loss, difficulty reasoning, confusion). Elderly patients who have experienced a stroke have a high risk of immediate complications, such as infections or fever. It has been found that these complications are strongly related to a higher risk of death or longterm disability (dependency). These complications are usually treated only when they become apparent by paracetamol (for pain or fever), infections (ceftriaxone) and nausea and vomiting (metoclopramide). The aim of this study is to find out whether giving these medications to stroke patients straight away can prevent these complications from occurring in the first place, and reduce the risks of long-term side-effects.

Who can participate?

Adults over 66 years of age with a clinical diagnosis of AIS or ICH.

What does the study involve?

Participants are randomly allocated into groups who will receive treatment with a combination of paracetamol, ceftriaxone and metoclopramide, or none of these drugs (usual care). The treatment is started within 12 hours of the stroke, and continues for four days (or until the

patient is discharged from hospital, if sooner). Three months later, participants are interviewed in order to assess whether they have any handicap following their stroke, and if so, how severe it is. Survival rates, quality of life and cognition (mental processes) are also measured.

What are the possible benefits and risks of participating?

A benefit of participating is that one or more of the drugs used in this study could help to reduce the change of death or dependency after a stroke, but this cannot be guaranteed. There are no significant risks of participating as the drugs used in this study have been used for decades in patients with acute stroke to treat fever (paracetamol), infections (ceftriaxone), and nausea and vomiting (metoclopramide). Common side effects from these drugs include diarrhoea and allergic reactions, however serious side effects are rare.

Where is the study run from?

- 1. Tartu University Hospital (Estonia)
- 2. Larissa University Hospital (Greece)
- 3. University of Debrecen (Hungary)
- 4. Carlo Poma Hospital (Italy)
- 5. University Medical Center Utrecht (Netherlands)
- 6. Oslo University Hospital (Norway)
- 7. Institute of Psychiatry and Neurology, Warsaw (Poland)
- 8. Royal Infirmary of Edinburgh (UK)

When is the study starting and how long is it expected to run for? June 2015 to September 2022

Who is funding the study? European Union's Horizon 2020 Research and Innovation Programme (Belgium)

Who is the main contact? Dr Bart van der Worp

Contact information

Type(s)

Public

Contact name

Dr Bart van der Worp

ORCID ID

https://orcid.org/0000-0001-9891-2136

Contact details

Department of Neurology and Neurosurgery Brain Center Rudolf Magnus G03.232 University Medical Center Utrecht Heidelberglaan 100 Utrecht Netherlands 3584CX

Type(s)

Scientific

Contact name

Dr Bart van der Worp

Contact details

Department of Neurology and Neurosurgery Brain Center Rudolf Magnus University Medical Center Utrecht G03.232 Heidelberglaan 100 Utrecht Netherlands 3584CX

Additional identifiers

Clinical Trials Information System (CTIS)

2015-003179-32

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

ToL54304

Study information

Scientific Title

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment

Acronym

PRECIOUS

Study objectives

Prevention of infections, fever, or aspiration with ceftriaxone, paracetamol, metoclopramide, or any combination of these in the first 4 days after stroke onset improves functional outcome at 3 months in elderly patients with acute stroke.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

International multi-centre multi-factorial randomized controlled open-label clinical trial with blinded outcome assessment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute ischaemic stroke or intracerebral haemorrhage

Interventions

Patients will be randomly allocated in a 2*2*2 factorial design to any combination of open-label oral or rectal metoclopramide (10 mg thrice daily), intravenous ceftriaxone (2000 mg once daily), oral, rectal, or intravenous paracetamol (1000 mg four times daily), or to usual care, started within 12 hours after symptom onset and continued for 4 days or until complete recovery or discharge from hospital, if earlier. Allocation will be based on proportional minimisation through a web-based allocation service. Investigators will have the opportunity to censor a single specific randomisation arm in a specific patient before randomisation, for example in case of an allergy to one of the interventions. Patients will have follow-up at 7 and 91 days.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Paracetamol, ceftriaxone, metoclopramide

Primary outcome(s)

Handicap as assessed with the score on the modified Rankin Scale at 91 days (\pm 14), and analysed with ordinal logistic regression.

Key secondary outcome(s))

At 7 days (± 1 day) or at discharge, if earlier:

- 1. Infections in the first 7 days (\pm 1 day; frequency, type, and C. difficile infections). Infections will be categorised as diagnosed by the clinician, and as judged by an independent adjudication committee (masked to treatment allocation):
- 2. Third generation cephalosporin resistance in the first 7 days (± 1 day), detected as part of routine clinical practice;
- 3. Antimicrobial use during the first 7 days (\pm 1 day), converted to units of defined daily doses according to the classification of the WHO Anatomical Therapeutic Chemical Classification System with Defined Daily Doses Index;
- 4. In a subgroup of patients: presence of Extended-Spectrum Beta-Lactamase (ESBL)-producing bacteria as detected by PCR in a rectal swab.

At 91 days (± 14 days):

- 1. Death:
- 2. Unfavourable functional outcome, defined as mRS 3 to 6;

- 3. Disability assessed with the score on the Barthel Index (BI);
- 4. Cognition assessed with the Montreal Cognitive Assessment (MoCA);
- 5. Quality of life assessed with the EuroQol 5D-5L (EQ-5D-5L);
- 6. Home time: duration of stay in the patient's own home or a relative's home over the first 90 days;
- 7. Patient location over first 91 days (± 14 days): hospital; rehabilitation service; chronic nursing facility; home;
- 8. SAEs in the first 14 days.

Completion date

30/09/2022

Eligibility

Key inclusion criteria

- 1. Clinical diagnosis of acute ischaemic stroke or intracerebral haemorrhage (confirmed with CT or MRI scan)
- 2. Score on the National Institutes of Health Stroke Scale 58 (NIHSS) ≥6, indicating moderately severe to severe stroke
- 3. Aged 66 years or older
- 4. Possibility to start trial treatment within 12 h of symptom onset

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Lower age limit

66 years

Sex

All

Total final enrolment

1493

Key exclusion criteria

All participants:

- 1. Active infection requiring antibiotic treatment, as judged by the treating physician;
- 2. Pre-stroke score on the modified Rankin Scale ≥4
- 3. Death appearing imminent at the time of assessment.

For the ceftriaxone arm:

1. Known hypersensitivity to beta-lactam antibiotics

For the paracetamol arm:

- 1. Known hypersensitivity to paracetamol or any of the excipients
- 2. Known severe hepatic insufficiency
- 3. Chronic alcoholism

For the metoclopramide arm:

- 1. Hypersensitivity to the metoclopramide or to any of the excipients
- 2. Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation of gastrointestinal motility constitutes a risk
- 3. Confirmed or suspected pheochromocytoma
- 4. History of neuroleptic or metoclopramide-induced tardive dyskinesia
- 5. Epilepsy
- 6. Parkinson's disease
- 7. Use of levodopa or dopaminergic agonists
- 8. Known history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5 deficiency

Date of first enrolment

01/02/2016

Date of final enrolment

30/06/2022

Locations

Countries of recruitment

United Kingdom

Scotland

Estonia

Germany

Greece

Hungary

Italy

Netherlands

Norway

Poland

Study participating centre Tartu University Hospital

Ülikooli 18

Tartu

Study participating centre University Medical Center Hamburg-Eppendorf

Martinistraße 52 Hamburg Germany 20246

Study participating centre Larissa University Hospital

Mezourlo Larissa Greece 38221

Study participating centre University of Debrecen

Debrecen Egyetem tér 1 Debrecen Hungary 4032

Study participating centre Carlo Poma Hospital

Strada Lago Paiolo, 10 Mantova, Mantua Italy 46100

Study participating centre University Medical Center Utrecht

Heidelberglaan 100 Utrecht Netherlands 3584CX

Study participating centre Oslo University Hospital

Kirkeveien 166 Ullevål Oslo Norway 0450

Study participating centre Institute of Psychiatry and Neurology

Sobieskiego 9 Warsaw Poland 02957

Study participating centre Royal Infirmary of Edinburgh

51 Little France Crescent Edinburgh United Kingdom EH16 4SA

Sponsor information

Organisation

University Medical Center Utrecht

ROR

https://ror.org/0575yy874

Funder(s)

Funder type

Research organisation

Funder Name

European Union's Horizon 2020 Research and Innovation Programme

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type Results article	Details	Date created 01/12/2023	Date added 11/12/2023	Peer reviewed? Yes	Patient-facing? No
Protocol article	protocol	01/09/2018		Yes	No
Abstract results Abstract results		03/05/2022 16/05/2017	10/10/2023 10/10/2023	No No	No No
Statistical Analysis Plan	statistical analysis plan	26/10/2020	28/10/2020	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes